What is Apnimed?
Apnimed is dedicated to discovering, developing, and commercializing innovative oral therapies for sleep-related breathing conditions, with a primary focus on obstructive sleep apnea (OSA). Its lead candidate, AD109, is engineered to target the root cause of airway collapse during sleep by addressing neuromuscular dysfunction. This approach aims to provide a less invasive alternative to current treatments such as devices or surgery. The company's strategic collaborations and capital infusions are geared towards advancing its late-stage clinical trials and preparing for potential regulatory submissions, positioning it as a key player in the sleep medicine sector.
How much funding has Apnimed raised?
Apnimed has raised a total of $380.3M across 6 funding rounds:
Series A
$15M
Series B
$25M
Series C
$142.3M
Debt
$23M
Private Equity
$25M
Debt
$150M
Series A (2020): $15M, investors not publicly disclosed
Series B (2021): $25M led by Morningside Venture Capital, Tao Capital Partners , LLC, and Seligman Investments
Series C (2023): $142.3M supported by Morningside Venture Capital, Sectoral Asset Management, Alpha Wave Ventures, Seligman Investments, Nexpoint Residential Trust, and Tao Capital Management
Debt (2025): $23M, investors not publicly disclosed
Private Equity (2026): $25M, investors not publicly disclosed
Debt (2026): $150M with participation from HealthCare Royalty Management
Key Investors in Apnimed
Morningside Venture Capital
Morningside Venture Capital, founded in 1986, is a private equity and venture capital firm with a focus on early-stage technology companies. They are known for their entrepreneurial investment professionals with deep industry knowledge.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in global healthcare equities, with a particular emphasis on biotech. They offer various public and private equity healthcare strategies.
Seligman Investments
Seligman Investments offers a diverse range of core investment portfolios, including fixed income, growth and income, growth, and value equity, with a history of solid long-term performance.
What's next for Apnimed?
With the recent influx of major strategic investment, Apnimed is poised to advance its clinical development programs and potentially move towards regulatory approval for its investigational therapies. The substantial enterprise-level funding indicates a strong belief in the company's technology and market potential. Future strategic moves will likely involve continued clinical trial execution, potential expansion of its therapeutic pipeline, and preparation for commercialization. The company's focus on addressing a significant unmet need in sleep medicine suggests a trajectory aimed at capturing a substantial share of this growing market.
See full Apnimed company page
